Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 6/2016

02.11.2016 | Pathophysiology of Myocardial Failure (I Anand and M Patarroyo-Aponte, Section Editors)

Heart Failure Secondary to Chagas Disease: an Emerging Problem in Non-endemic Areas

verfasst von: Mahmoud Traina, Sheba Meymandi, Jason S. Bradfield

Erschienen in: Current Heart Failure Reports | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Chagas disease affects millions of people worldwide. Though the majority of infected individuals remain asymptomatic, approximately 30 % of patients progress to develop cardiac manifestations and eventual heart failure. While vectorial transmission occurs predominantly in South America, Central America, and Mexico, millions of people originally from these endemic regions immigrate to non-endemic countries in North America, Europe, and Asia. Outside of rare specialized centers, health-care providers lack experience diagnosing and treating this disease. This lack of experience likely leads to far fewer Chagas disease patients being diagnosed than what actually exist in non-endemic countries, with subsequent adverse effect on patient outcomes and health-care expenses. Underdiagnosis increases the risk of developing cardiomyopathy, associated heart failure, and life-threatening ventricular arrhythmias as the disease progresses.
Literatur
1.
2.
Sarkar S, Strutz SE, Frank DM, Rivaldi CL, Sissel B, Sanchez-Cordero V. Chagas disease risk in Texas. PLoS Negl Trop Dis. 2010;4.
3.
Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, et al. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion. 2012;52:1922–30.CrossRefPubMed
4.
Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, Gamboa-Leon R, et al. Mother-to-child transmission of Chagas’ disease in North America: why don’t we do more? Matern Child Health J. 2008;12:283–6.CrossRefPubMed
5.
• Requena-Mendez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DA, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9:e0003540. This systemic review and meta-analysis is an essential study that helps better quantify the prevalence of CD in Latin American immigrants living in Europe.
6.
Leiby DA, Herron Jr RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 2002;42:549–55.CrossRefPubMed
7.
Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S, et al. Chagas disease and transfusion medicine: a perspective from non-endemic countries. Blood Transfus. 2015;13:540–50.PubMedPubMedCentral
8.
Kirchhoff LV, Gam AA, Gilliam FC. American trypanosomiasis (Chagas’ disease) in Central American immigrants. Am J Med. 1987;82:915–20.CrossRefPubMed
9.
10.
Dorn PL, Perniciaro L, Yabsley MJ, Roellig DM, Balsamo G, Diaz J, et al. Autochthonous transmission of Trypanosoma cruzi. Louisiana Emerg Infect Dis. 2007;13:605–7.CrossRefPubMed
11.
Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49:e52–4.CrossRefPubMed
12.
Traina MIKL, Khamag H, Padilla Garcia E, Meymandi S. Community-based study of prevalence of Chagas disease in Los Angeles County. 2010.
13.
Piron M, Verges M, Munoz J, Casamitjana N, Sanz S, Maymo RM, et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion. 2008;48:1862–8.CrossRefPubMed
14.
Avila Arzanegui O, Liendo Arenaza P, Martinez Indart L, Martinez Astorkiza T, Pocheville Guruceta MI, Egurbide Arberas MV. Prevalence of Trypanosoma cruzi infection and vertical transmission in Latin-American pregnant women in a health area of Biscay. Enferm Infecc Microbiol Clin. 2013;31:210–6.CrossRefPubMed
15.
Barona-Vilar C, Gimenez-Marti MJ, Fraile T, Gonzalez-Steinbauer C, Parada C, Gil-Brusola A, et al. Prevalence of Trypanosoma cruzi infection in pregnant Latin American women and congenital transmission rate in a non-endemic area: the experience of the Valencian Health Programme (Spain). Epidemiol Infect. 2012;140:1896–903.CrossRefPubMed
16.
Munoz J, Coll O, Juncosa T, Verges M, del Pino M, Fumado V, et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona. Spain Clin Infect Dis. 2009;48:1736–40.CrossRefPubMed
17.
Navarro M, Navaza B, Guionnet A, Lopez-Velez R. Chagas disease in Spain: need for further public health measures. PLoS Negl Trop Dis. 2012;6:e1962.CrossRefPubMedPubMedCentral
18.
Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102 Suppl 1:75–85.CrossRefPubMed
19.
Steele LS, MacPherson DW, Kim J, Keystone JS, Gushulak BD. The sero-prevalence of antibodies to trypanosoma cruzi in Latin American refugees and immigrants to Canada. J Immigr Minor Health. 2007;9:43–7.CrossRefPubMed
20.
Jackson Y, Myers C, Diana A, Marti HP, Wolff H, Chappuis F, et al. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg Infect Dis. 2009;15:601–3.CrossRefPubMedPubMedCentral
21.
Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O. Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol. 2014;103:1–10.CrossRefPubMed
22.
Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010;115:22–7.CrossRefPubMed
23.
Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, Seixas J, Van Gool T, Canavate C, Flores-Chavez M, Jackson Y, Chiodini PL, Albajar-Vinas P and Working Group on Chagas D. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill. 2011;16.
24.
Munoz J, Gomez i Prat J, Gallego M, Gimeno F, Trevino B, Lopez-Chejade P, et al. Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop. 2009;111:51–5.CrossRefPubMed
25.
Requena-Mendez A, Moore DA, Subira C, Munoz J. Addressing the neglect: Chagas disease in London. UK Lancet Glob Health. 2016;4:e231–3.CrossRefPubMed
26.
Pinto A, Pett S, Jackson Y. Identifying Chagas disease in Australia: an emerging challenge for general practitioners. Aust Fam Physician. 2014;43:440–2.PubMed
27.
Jackson Y, Pinto A, Pett S. Chagas disease in Australia and New Zealand: risks and needs for public health interventions. Trop Med Int Health. 2014;19:212–8.CrossRefPubMed
28.
Imai K, Maeda T, Sayama Y, Osa M, Mikita K, Kurane I, et al. Chronic Chagas disease with advanced cardiac complications in Japan: case report and literature review. Parasitol Int. 2015;64:240–2.CrossRefPubMed
29.
Kapelusznik L, Varela D, Montgomery SP, Shah AN, Steurer FJ, Rubinstein D, et al. Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis. 2013;57:e7.CrossRefPubMed
30.
• Traina MI, Sanchez DR, Hernandez S, Bradfield JS, Labedi MR, Ngab TA, et al. Prevalence and impact of Chagas disease among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles. California Circ Heart Fail. 2015;8:938–43. This study demonstrates both the high prevalence of CD in Latin American immigrants living in Los Angeles with cardiomyopathy, but also the increased adverse event rate in the CD patients compared to patients with other etiologies for their non-ischemic cardiomyopathy.
31.
Sanchez-Montalva A, Salvador F, Rodriguez-Palomares J, Sulleiro E, Sao-Aviles A, Roure S, et al. Chagas cardiomyopathy: usefulness of EKG and echocardiogram in a non-endemic country. PLoS One. 2016;11:e0157597.CrossRefPubMedPubMedCentral
32.
Stimpert KK, Montgomery SP. Physician awareness of Chagas disease. USA Emerg Infect Dis. 2010;16:871–2.CrossRefPubMed
33.
El Ghouzzi MH, Boiret E, Wind F, Brochard C, Fittere S, Paris L, et al. Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening. Transfusion. 2010;50:575–83.CrossRefPubMed
34.
Atsma F, de Vegt F. The healthy donor effect: a matter of selection bias and confounding. Transfusion. 2011;51:1883–5.CrossRefPubMed
35.
Torrico F, Alonso-Vega C, Suarez E, Rodriguez P, Torrico MC, Dramaix M, et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg. 2004;70:201–9.PubMed
36.
Buekens P, Cafferata ML, Alger J, Althabe F, Belizan JM, Carlier Y, et al. Congenital transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: study protocol. Reprod Health. 2013;10:55.CrossRefPubMedPubMedCentral
37.
Centers for Disease C and Prevention. Congenital transmission of Chagas disease—Virginia, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:477–9.
38.
Leiby DA, Read EJ, Lenes BA, Yund AJ, Stumpf RJ, Kirchhoff LV, et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas’ disease, in US blood donors. J Infect Dis. 1997;176:1047–52.CrossRefPubMed
39.
Leiby DA, Fucci MH, Stumpf RJ. Trypanosoma cruzi in a low- to moderate-risk blood donor population: seroprevalence and possible congenital transmission. Transfusion. 1999;39:310–5.CrossRefPubMed
40.
Sanchez DR, Traina MI, Hernandez S, Smer AM, Khamag H, Meymandi SK. Chagas disease awareness among Latin American immigrants living in Los Angeles. California Am J Trop Med Hyg. 2014;91:915–9.CrossRefPubMed
41.
Blasco-Hernandez T, Miguel LG, Navaza B, Navarro M, Benito A. Knowledge and experiences of Chagas disease in Bolivian women living in Spain: a qualitative study. Glob Health Action. 2016;9:30201.PubMed
42.
Minneman RM, Hennink MM, Nicholls A, Salek SS, Palomeque FS, Khawja A, et al. Barriers to testing and treatment for Chagas disease among Latino immigrants in Georgia. J Parasitol Res. 2012;2012:295034.CrossRefPubMedPubMedCentral
43.
Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis. 2009;3:e488.CrossRefPubMedPubMedCentral
44.
Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724–34.CrossRefPubMed
45.
Molina I, Gomez i Prat J, Salvador F, Trevino B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370:1899–908.CrossRefPubMed
46.
• Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi Jr A, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373:1295–306. This prospective mulit-center trial (BENEFIT) compared benznidazole to placebo for the treatment of CD in patient with documented cardiomyopathy.
47.
Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis. 2010;51:e69–75.CrossRefPubMed
48.
Miller DA, Hernandez S, De Armas Rodriguez L, Eells SJ, Traina MM, Miller LG, et al. Tolerance of benznidazole in a United States Chagas disease clinic. Clin Infect Dis. 2015;60:1237–40.CrossRefPubMed
49.
Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013;13:342–8.CrossRefPubMedPubMedCentral
50.
Rassi Jr A, Rassi SG, Rassi A. Sudden death in Chagas’ disease. Arq Bras Cardiol. 2001;76:75–96.CrossRefPubMed
51.
Lee-Felker SA, Thomas M, Felker ER, Traina M, Salih M, Hernandez S, et al. Value of cardiac MRI for evaluation of chronic Chagas disease cardiomyopathy. Clin Radiol. 2016;71:618 e1–7.CrossRef
52.
Barbosa MP, da Costa Rocha MO, de Oliveira AB, Lombardi F, Ribeiro AL. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease. Europace. 2013;15:957–62.CrossRefPubMed
53.
Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes 3rd NA, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2012;126:1784–800.CrossRefPubMed
54.
Sosa E, Scanavacca M, d’Avila A, Pilleggi F. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Electrophysiol. 1996;7:531–6.CrossRefPubMed
55.
Sosa E, Scanavacca M, D’Avila A, Bellotti G, Pilleggi F. Radiofrequency catheter ablation of ventricular tachycardia guided by nonsurgical epicardial mapping in chronic Chagasic heart disease. Pacing Clin Electrophysiol. 1999;22:128–30.CrossRefPubMed
56.
Saenz LC, Corrales FM, Bautista W, Traina M, Meymandi S, Rodriguez DA, Tellez LJ, Vaseghi M, Garcia F, Shivkumar K, Bradfield JS. Cardiac sympathetic denervation for intractable ventricular arrhythmias in Chagas disease. Heart Rhythm. 2016.
57.
Armaganijan LV, Staico R, Moreira DA, Lopes RD, Medeiros PT, Habib R, et al. 6-month outcomes in patients with implantable cardioverter-defibrillators undergoing renal sympathetic denervation for the treatment of refractory ventricular arrhythmias. JACC Cardiovasc Interv. 2015;8:984–90.CrossRefPubMed
58.
Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg. 2001;71:1833–8.CrossRefPubMed
59.
Kransdorf EP, Czer LS, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant. 2013;13:3262–8.CrossRefPubMed
60.
Requena-Mendez A, Albajar-Vinas P, Angheben A, Chiodini P, Gascon J, Munoz J, et al. Health policies to control Chagas disease transmission in European countries. PLoS Negl Trop Dis. 2014;8:e3245.CrossRefPubMedPubMedCentral
Metadaten
Titel
Heart Failure Secondary to Chagas Disease: an Emerging Problem in Non-endemic Areas
verfasst von
Mahmoud Traina
Sheba Meymandi
Jason S. Bradfield
Publikationsdatum
02.11.2016
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 6/2016
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-016-0305-9

Weitere Artikel der Ausgabe 6/2016

Current Heart Failure Reports 6/2016 Zur Ausgabe

Comorbidities of Heart Failure (C Angermann, Section Editor)

Obstructive Ventilatory Disorder in Heart Failure—Caused by the Heart or the Lung?

Comorbidities of Heart Failure (C Angermann, Section Editor)

Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications

Management of Heart Failure (T Meyer, Section Editor)

New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure

Pathophysiology of Myocardial Failure (I Anand and M Patarroyo-Aponte, Section Editors)

Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications

Pathophysiology of Myocardial Failure (I Anand and M Patarroyo-Aponte, Section Editors)

New Challenges in the Treatment of Patients With Left Ventricular Support: LVAD Thrombosis

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise